Latest News
- September 12, 2025Join CBCC at CPHI Frankfurt 2025
- August 08, 2025International Publication of Phase II clinical Trial
- August 06, 2025Experience Agility-driven clinical trials with CBCC!
- July 23, 2025Discover the drive for swiftness in clinical research!
- July 16, 2025ANDA Approval Doxorubicin Hydrochloride Liposome
July 16, 2025
ANDA Approval Doxorubicin Hydrochloride Liposome
ANDA application for Doxorubicin Hydrochloride Liposome Injection supported by CBCC has received approval from the USFDA!
Type of Application: 505 (j)
Therapeutic Area: Oncology
Scope: End-to-end clinical trial management
Country of Trial Execution: India
CBCC Global Research: Benchmarked to Global Standards of Excellence
Manoj Vyas Dr. Sandeep Singh Jaimeen Vanparia Sanjeev Ganatra Nikhil Gandhi Harakh Shah, PMP® Tapan Shah Kinnari Gandhi RQAP-GCP Dr. Praveen Choudhary Nikunj Patel Ankit Parikh Ajit Upadhyaya Ankit Pandav Devang Pandya Jay Vyas Udayan Vyas
ClinicalResearch PharmaceuticalScience Oncology DrugDevelopment
ClinicalTrials MedicalResearch